000162912 001__ 162912
000162912 005__ 20240320115515.0
000162912 0247_ $$2pmc$$apmc:PMC9200694
000162912 0247_ $$2doi$$a10.1007/s00115-021-01206-w
000162912 0247_ $$2pmid$$apmid:34652485
000162912 0247_ $$2ISSN$$a0028-2804
000162912 0247_ $$2ISSN$$a1433-0407
000162912 0247_ $$2altmetric$$aaltmetric:115359607
000162912 037__ $$aDZNE-2021-01565
000162912 041__ $$aGerman
000162912 082__ $$a610
000162912 1001_ $$0P:(DE-2719)9000458$$aHaussmann, Robert$$b0$$eCorresponding author$$udzne
000162912 245__ $$aIntrazerebrale Blutungen unter Plättchenaggregationshemmung und oraler Antikoagulation bei Patienten mit zerebraler Amyloidangiopathie.
000162912 260__ $$aHeidelberg$$bSpringer$$c2022
000162912 3367_ $$2DRIVER$$aarticle
000162912 3367_ $$2DataCite$$aOutput Types/Journal article
000162912 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1657544946_30472$$xReview Article
000162912 3367_ $$2BibTeX$$aARTICLE
000162912 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000162912 3367_ $$00$$2EndNote$$aJournal Article
000162912 500__ $$a(CC BY)
000162912 520__ $$aOral anticoagulation in patients with cerebral amyloid angiopathy is a therapeutic challenge. The association of cerebral amyloid angiopathy with intracerebral hemorrhage, a high mortality of intracerebral hemorrhage especially under oral anticoagulation and the high risk of recurrent bleeding require a multidisciplinary approach and a thorough risk-benefit analysis. Vitamin K antagonists increase the risk of intracerebral bleeding and the accompanying mortality by 60% and should be avoided if possible or reserved for special clinical situations (e.g. mechanical aortic valve replacement). Treatment with novel oral anticoagulants and antiplatelet drugs also increases the risk of cerebral bleeding and therefore needs a thorough risk-benefit evaluation. An interventional left atrial appendage closure is a promising therapeutic option especially in patients with an absolute arrythmia with atrial fibrillation. Furthermore, other clinical implications in patients with cerebral amyloid angiopathy are the subject of this review of the literature, such as special characteristics after acute ischemic stroke and the necessary secondary prophylaxis, with previous intracerebral hemorrhage and in patients with cognitive deficits.
000162912 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000162912 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000162912 650_7 $$2Other$$aCerebral amyloid angiopathy
000162912 650_7 $$2Other$$aInterventional left atrial appendage closure
000162912 650_7 $$2Other$$aIntracerebral hemorrhage
000162912 650_7 $$2Other$$aOral anticoagulation
000162912 650_7 $$2Other$$aPlatelet inhibition
000162912 650_2 $$2MeSH$$aAnticoagulants: therapeutic use
000162912 650_2 $$2MeSH$$aAtrial Fibrillation: complications
000162912 650_2 $$2MeSH$$aAtrial Fibrillation: drug therapy
000162912 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: complications
000162912 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: diagnosis
000162912 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: drug therapy
000162912 650_2 $$2MeSH$$aCerebral Hemorrhage: chemically induced
000162912 650_2 $$2MeSH$$aCerebral Hemorrhage: complications
000162912 650_2 $$2MeSH$$aCerebral Hemorrhage: diagnosis
000162912 650_2 $$2MeSH$$aHumans
000162912 650_2 $$2MeSH$$aIschemic Stroke
000162912 650_2 $$2MeSH$$aStroke: complications
000162912 7001_ $$aHomeyer, P.$$b1
000162912 7001_ $$aHaußmann, M.$$b2
000162912 7001_ $$0P:(DE-2719)2812107$$aBrandt, Daniel Moritz$$b3$$udzne
000162912 7001_ $$0P:(DE-2719)2501739$$aDonix, M.$$b4$$udzne
000162912 7001_ $$aPuetz, V.$$b5
000162912 7001_ $$aLinn, J.$$b6
000162912 773__ $$0PERI:(DE-600)1462945-8$$a10.1007/s00115-021-01206-w$$n6$$p599-604$$tDer Nervenarzt$$v93$$x1433-0407$$y2022
000162912 8564_ $$uhttps://link.springer.com/article/10.1007%2Fs00115-021-01206-w
000162912 8564_ $$uhttps://pub.dzne.de/record/162912/files/DZNE-2021-01565.pdf$$yOpenAccess
000162912 8564_ $$uhttps://pub.dzne.de/record/162912/files/DZNE-2021-01565.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000162912 909CO $$ooai:pub.dzne.de:162912$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000162912 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000458$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000162912 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000458$$aExternal Institute$$b0$$kExtern
000162912 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812107$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000162912 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2501739$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000162912 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000162912 9141_ $$y2022
000162912 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000162912 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000162912 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000162912 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000162912 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000162912 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000162912 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNERVENARZT : 2021$$d2022-11-12
000162912 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000162912 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-28$$wger
000162912 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000162912 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000162912 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000162912 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-12
000162912 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000162912 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000162912 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000162912 9201_ $$0I:(DE-2719)1710008$$kAG Donix$$lClinical planning and intersite group$$x0
000162912 980__ $$ajournal
000162912 980__ $$aVDB
000162912 980__ $$aUNRESTRICTED
000162912 980__ $$aI:(DE-2719)1710008
000162912 9801_ $$aFullTexts